Capricor Therapeutics Inc CAPR.OQ CAPR.O is expected to show a fall in quarterly revenue when it reports results on August 11 for the period ending June 30 2025
The San Diego California-based company is expected to report a 80.4% decrease in revenue to $778 thousand from $3.97 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data. (Majority is on total revenue basis including milstone and other revenue)
LSEG's mean analyst estimate for Capricor Therapeutics Inc is for a loss of 47 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Capricor Therapeutics Inc is $21.50, about 57.8% above its last closing price of $9.07
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.31 | -0.32 | -0.53 | Missed | -67.4 |
Dec. 31 2025 | -0.32 | -0.26 | -0.16 | Beat | 39.2 |
Sep. 30 2024 | -0.35 | -0.36 | -0.38 | Missed | -6 |
Jun. 30 2024 | -0.35 | -0.36 | -0.35 | Beat | 1.7 |
Mar. 31 2024 | -0.11 | -0.11 | -0.31 | Missed | -173.5 |
Dec. 31 2023 | -0.10 | -0.09 | -0.02 | Beat | 77.8 |
Sep. 30 2023 | -0.29 | -0.29 | -0.25 | Beat | 13.8 |
Jun. 30 2023 | -0.35 | -0.35 | -0.29 | Beat | 17.1 |
This summary was machine generated August 8 at 23:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)